KELLY LOHMANN: Open Payments
NPI 1417275629 · SILVER SPRING, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$31,199 in 150 payments from 12 companies in 2025. Trend: 2023 $11,323 · 2024 $24,719 · 2025 $31,199
Speaker / faculty: $21,970Consulting: $3,820Food & beverage: $3,244Travel & lodging: $2,165
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 56 | $23,367 |
| ABBVIE INC. | 37 | $6,252 |
| Otsuka America Pharmaceutical, Inc. | 13 | $296 |
| Neurocrine BioSciences, Inc. | 9 | $267 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $244 |
| Vanda Pharmaceuticals Inc. | 3 | $172 |
| E.R. Squibb & Sons, L.L.C. | 8 | $155 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Axsome Therapeutics, Inc. | 4 | $94 |
| Lundbeck LLC | 5 | $91 |
Products named: LYBALVI, VRAYLAR, ARISTADA, INGREZZA, CAPLYTA, INVEGA SUSTENNA, COBENFY, FANAPT.
Industry payments across MD — which companies pay providers there.
